These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12186268)

  • 1. Positive modulators of AMPA receptors as a potential treatment for schizophrenia.
    Danysz W
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1062-6. PubMed ID: 12186268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors.
    Suppiramaniam V; Bahr BA; Sinnarajah S; Owens K; Rogers G; Yilma S; Vodyanoy V
    Synapse; 2001 May; 40(2):154-8. PubMed ID: 11252027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
    Amargós-Bosch M; Adell A; Artigas F
    J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CX-516 Cortex pharmaceuticals.
    Danysz W
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1081-8. PubMed ID: 12186271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions between ampakines and antipsychotic drugs.
    Johnson SA; Luu NT; Herbst TA; Knapp R; Lutz D; Arai A; Rogers GA; Lynch G
    J Pharmacol Exp Ther; 1999 Apr; 289(1):392-7. PubMed ID: 10087029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.
    Roberts BM; Holden DE; Shaffer CL; Seymour PA; Menniti FS; Schmidt CJ; Williams GV; Castner SA
    Behav Brain Res; 2010 Sep; 212(1):41-8. PubMed ID: 20347881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiological background for the development of new drugs in schizophrenia.
    López-Muñoz F; Álamo C
    Clin Neuropharmacol; 2011; 34(3):111-26. PubMed ID: 21586917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate-based therapeutic approaches: ampakines.
    Lynch G
    Curr Opin Pharmacol; 2006 Feb; 6(1):82-8. PubMed ID: 16361116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way.
    Ballew N
    Chem Biol; 2003 Nov; 10(11):1003-4. PubMed ID: 14652066
    [No Abstract]   [Full Text] [Related]  

  • 13. AMPA receptor modulators as cognitive enhancers.
    Lynch G
    Curr Opin Pharmacol; 2004 Feb; 4(1):4-11. PubMed ID: 15018832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in positive allosteric modulators of the AMPA receptor.
    Morrow JA; Maclean JK; Jamieson C
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):571-9. PubMed ID: 17002217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine.
    Yarotskyy V; Glushakov AV; Sumners C; Gravenstein N; Dennis DM; Seubert CN; Martynyuk AE
    Mol Pharmacol; 2005 May; 67(5):1648-54. PubMed ID: 15687225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.